NCT06140953 - Benefits of Trimetazidine in MASLD Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 10, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

November 30, 2024

Conditions

Metabolic Associated Fatty Liver Disease

Interventions

DRUG

Trimetazidine

trimetazidine at dose 20 mg three times daily to be taken by intervention group

DRUG

Conventional therapy

conventional therapy

DRUG

Placebo

placebo tablet (inert substance has the same shape and color of intervention) to be taken by control group only

Trial Locations (1)

Beni-Suef university, Banī Suwayf

All Listed Sponsors

lead

October 6 University

OTHER